# SVE Capital

> SVE Capital is a VC fund backing Biotechnology, Health Care and Therapeutics. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 8
- Last investment: Jan 2023
- Lead investor: 0%
- Last updated: Aug 2026

SVE Capital is an investment Firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 50% |
| Health Care | 3 | 38% |
| Therapeutics | 3 | 38% |
| Medical | 2 | 25% |
| Genetics | 1 | 13% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 25% |
| Series A | 2 | 25% |
| Series B | 1 | 13% |
| Series C | 1 | 13% |
| Funding Round | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SetPoint Medical | SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $80M |  | Jan 19, 2023 |  |
| SetPoint Medical | SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $80M | Series C | Jan 19, 2023 |  |
| Amplicore | Amplicore develops injectable and minimally invasive therapeutics for musculoskeletal disorders. | $4M | Seed | Mar 25, 2021 |  |
| SetPoint Medical | SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $64M |  | Jan 27, 2021 |  |
| SetPoint Medical | SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $64M | Series B | Jan 27, 2021 |  |
| SwineTech | SwineTech is a mechanical and industrial engineering company that bridges the gap between producers and pigs through artificial intelligence and sensor-based technologies. The company specializes in the fields of machine learning, audio, and pork production. SwineTech was founded in 2015 and headquartered in Cedar Rapids, Iowa. | $5M | Series A | Mar 13, 2020 |  |
| Valitor | Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Their technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. They currentlyhave three development pipelines in the fields of dermatology, ophthalmology, and orthopedics that highlight the capabilities of their novel drug products.​ | $2.5M | Series A | Sep 20, 2018 |  |
| DNALite Therapeutics | DNALite Therapeutics, Inc. is an early-stage preclinical biotechnology company committed on bringing the next-generation of drugs to the gastrointestinal tract. Currently for some gastrointestinal diseases, such as colorectal cancer and Crohn's disease, complete or partial removal of the colon and/or rectum is the only treatment Our aimis to prevent not manage the progression of theses diseases. We are doing this by harnessing our proprietary technology to carry DNA to cells that drive these diseases. | $1.5M | Seed | Aug 08, 2018 |  |

8 of 8 investments shown.

## Co-investors
- [Action Potential Venture Capital](https://shizune.co/investors/profile/action-potential-venture-capital) — VC Fund, 4 deals together
- [Berkeley Catalyst Fund (BCF)](https://shizune.co/investors/profile/berkeley-catalyst-fund-bcf) — VC Fund, 4 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 4 deals together
- [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures) — VC Fund, 4 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 4 deals together
- [Richard King Mellon Foundation](https://shizune.co/investors/profile/richard-king-mellon-foundation) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does SVE Capital invest in?

SVE Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did SVE Capital last invest?

The most recent investment recorded for SVE Capital closed in Jan 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co